WO2003061699A1 - Remedes pour affections allergiques - Google Patents

Remedes pour affections allergiques Download PDF

Info

Publication number
WO2003061699A1
WO2003061699A1 PCT/JP2002/013806 JP0213806W WO03061699A1 WO 2003061699 A1 WO2003061699 A1 WO 2003061699A1 JP 0213806 W JP0213806 W JP 0213806W WO 03061699 A1 WO03061699 A1 WO 03061699A1
Authority
WO
WIPO (PCT)
Prior art keywords
allergic
alkyl
compound
therapeutic agent
hydrogen atom
Prior art date
Application number
PCT/JP2002/013806
Other languages
English (en)
Japanese (ja)
Inventor
Hiroyuki Iwamura
Yoshifumi Ueda
Original Assignee
Japan Tobacco, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco, Inc. filed Critical Japan Tobacco, Inc.
Priority to US10/375,057 priority Critical patent/US20030232855A1/en
Publication of WO2003061699A1 publication Critical patent/WO2003061699A1/fr
Priority to US10/734,577 priority patent/US20040171613A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a new use of cannabinoid receptor modulators. More specifically, the present invention relates to the use of a modulator which selectively acts on a cannapinoid receptor, particularly a peripheral cell type receptor (also referred to as CB2), as a therapeutic agent for allergic diseases. Allergic diseases of N- (benzo [1,3] dioxol-5-ylmethyl) -7-methoxy-2_oxo-18-pentyloxy-1,2-dihydroquinoline-13-potolupoxamide or a pharmaceutically acceptable salt thereof It relates to a new use as a therapeutic agent.
  • a modulator which selectively acts on a cannapinoid receptor, particularly a peripheral cell type receptor (also referred to as CB2)
  • Cannabis has been used since ancient times for pain relief, antipyretics, and hypnosis, and has been used as a medicine. In Japan, it was listed as Indian Cannabis in the Pharmacopoeia until 1886-1951, and was used as an analgesic and anesthetic. In the United States of America, alcoholic solvent for cannabis was recognized as a drug for rheumatism, asthma, and tonsillitis in the Pharmacopoeia until 1850-194.
  • ⁇ 9-tetrahydrocannabinol which is considered to be a major component of cannabis or its psychoactive manifestation, has visual and auditory abnormalities, temporal and spatial cognitive abnormalities, increased implicitness, and thinking ability. It is known to cause a decrease in autonomy and memory impairment, causing marked changes in mental function.
  • the other pharmacological actions are also very diverse and include ataxia, increased irritability, hypothermia, respiratory depression, increased heart rate, stimulatory action, increased blood pressure, vasodilation, Its immunosuppressive activity, biomass, etc. have been reported, and its use is currently limited.
  • a series of hallucinogenic substances contained in cannabis are collectively called cannovinoides, and more than 60 cannapinoids including THC have been found at present.
  • CB1 The distribution of CB1 is detected in many tissues such as human testis, human prostate, ovaries, uterus, bone marrow, thymus, tonsils, pituitary gland, adrenal glands, heart, lungs, stomach, large intestine, bile ducts, leukocytes, etc. Its levels are much lower than in the brain. In contrast, CB2 was not found in rat brain but was found in monocytes in the marginal zone of the spleen. In human spleen, leukocytes, tonsils, thymus, and teng, CB2 is present at much higher levels than CB1.
  • CB 1 and CB 2 The identity of the two subtypes of receptor (CB 1 and CB 2) and the presence of endogenous ligands such as anandamide and 1-arachidonylglycerol were confirmed, and their physiological roles were examined. As a result, it was found that CB2 suppresses the proliferation of T cells and B cells and induces apoptosis to exhibit immunosuppressive effects. CB1-deficient knockout mice do not show the central effect seen with cannabinoid administration; CB2-deficient knockout mice Various findings are being obtained, such as the lack of suppression of T helper cell activation by cannapinide.
  • non-selective cannabinoid dress receptor ligands include ⁇ 9 —THC, CP55940, WIN55212-2, HU-243, HU-210, etc., and SR141716A, LY320135, arachidonol-2 ′ -Cloguchiethylamide, CP56667 and the like, and CB2 selective ligands such as SR144528, AM630, HU-308, ⁇ WH-051, L-768242 and the like are known (for example, Non-Patent Document 1 and Non-Patent Documents). 2). About allergy>
  • allergic diseases particularly allergic dermatitis and allergic asthma will be described.
  • Allergy is recognized as a hypersensitivity reaction of the living body based on the antigen-antibody reaction, and is different from the usual inflammatory response characterized by accumulation of monocytes-macrophages, neutrophils, etc. Eosinophils, basophils, mast cells contribute significantly.
  • Allergic reactions are currently generally categorized into four types. Instead of these four reactions occurring independently of each other, several types of reactions may occur simultaneously.
  • an antigen enters the body, it is first taken up by antigen presenting cells such as macrophages. Antigen-presenting cells transmit the information of the taken-in antigen to T cells. In addition, T cells instruct B cells to produce antigen-specific IgE antibodies. IgE antibodies bind to mast cells, which renders mast cells sensitized.
  • the fertilized cells release cytokines such as various chemical mediators such as histamine, eosinophil chemotactic factor, leukotriene, and the like.
  • cytokines such as various chemical mediators such as histamine, eosinophil chemotactic factor, leukotriene, and the like.
  • This reaction is called an immediate allergic reaction or a type I allergic reaction because it occurs within 30 minutes after the antigen enters. Normally, an immediate reaction lasts about an hour.
  • Representative diseases include anaphylaxis, allergic rhinitis, hay fever, jungle rash, allergic gastroenteropathy and the like.
  • Type I allergic reaction is also called cell lysis, and is a reaction in which complement acts on IgM or IgG antibodies bound to antigens to lyse cells by making a hole in the cell membrane.
  • macrophage killer cells act on cells that have received antibody binding to release damaging substances and destroy cells and tissues. Representative diseases include hemolytic anemia, thrombocytopenic purpura, myasthenia gravis, and Goodpasschair syndrome.
  • an antigen-antibody complex consisting of an antigen and an antibody (IgG antibody) is deposited on tissues without being processed by phagocytic cells, and complement, macrophages, and neutrophils gather there and become inflamed Cause disruption to the organization.
  • Representative diseases include acute glomerulonephritis due to streptococcus, rheumatoid arthritis, collagen disease, serum sickness, viral hepatitis, and allergic alveolitis.
  • Type IV allergic reactions do not involve antibodies, unlike types 1-3.
  • T cells release cytokines, migrate immune cells such as lymphocytes, neutrophils, and macrophages to break down antigens, but at the same time cause inflammation and tissue Causes destruction. If the invading antigen is a cell, killer T cells destroy the antigen.
  • the reaction usually takes one to two days to complete, and is also called a "delayed allergic reaction.” Tuberculin reaction, tuberculosis lesions, occlusal reaction after organ transplantation, dermatitis such as rash, cosmetic rash, etc. are type IV allergic reactions.
  • allergic asthma atopic dermatitis
  • allergic rhinitis atopic dermatitis
  • allergic conjunctivitis a chronic inflammation
  • Asthma is known as “allergic asthma” induced by allergens and non-allergic asthma induced by cold, exercise, etc., regardless of specific allergens.
  • asthma or “bronchial asthma” was characterized by reversible airflow limitation (airway obstruction) and airway hypersensitivity, but the airways of asthma include upper airway peeling and fibers just below the basement membrane. (E.g., thickening of the basement membrane) and the presence of chronic inflammation characterized by eosinophil aggregation, and are now recognized as chronic inflammatory diseases.
  • Many inflammatory cells such as eosinophils, T cells, and mast cells, are thought to be involved in airway inflammation, mast cells for immediate reactions, eosinophils for late reactions, and eosinophils and CD4 for delayed reactions. The involvement of positive helper T cells is considered important.
  • Anti-asthmatics have transitioned from bronchodilator-centered treatment for reversible airway obstruction to anti-inflammatory-centered treatment for chronic inflammation.
  • the treatment time of seizure depending on the conditions, short-acting i3 2 agonists, short-acting Te Ofuirin agents, inhaled anticholinergics, injection, oral, steroids and the like Ru is used.
  • antiallergic agents (mediator terpolymer release inhibitors, histamine ⁇ antagonists, Roikotoryen antagonists, Thromboxane A2 inhibitor ', Th2 cytokine inhibitor) has been used.
  • side effects such as suppression of adrenal function found in steroids, as well as symptoms of low effects (resistance) such as steroids and leukotriene antagonists are known, and further anti-asthmatic drugs are expected.
  • Atopic asthma or atopic dermatitis has a family or medical history This is a symptom that shows an allergic disease. Since atopic asthma and dermatitis often occur in children, a therapeutic drug with fewer side effects is particularly desirable.
  • Atopic predisposition (1) Family history, medical history (one or more diseases of bronchial asthma, allergic rhinitis, conjunctivitis, atopic dermatitis), or (2) Predisposition to produce IgE antibodies " It is distinguished from other inflammatory skin diseases.
  • Symptoms include skin irritation and dryness, and characteristic eruptions (erythema, papules, crusts, scales, rickets, prurigo, etc.) follow a chronic and repetitive course. In addition, it causes complications such as chicken pox varicella rash, virus infection (simple herpes virus infection, etc.), impetigo, and infectious molluscs (cataract, retinal detachment, etc.).
  • IgE 'mast cells In atopic dermatitis, the pathology is thought to involve immediate and delayed allergic reactions by IgE 'mast cells, as well as delayed allergic reactions by Langerhans cells and T cells.
  • pharmacotherapy is used depending on the symptoms, in combination with food, the cause of mites, etc., removal of exacerbating factors, and skin care (keeping skin clean, using a moisturizer to prevent skin drying). .
  • Antihistamines are used for pruritus, but their effect is not as pronounced as in the case of juniper.
  • topical steroid preparations are used in principle. It is considered that it is difficult to control dermatitis by using an oral anti-hydamine or allergic drug as a supplement. In general, atopic dermatitis is intractable, and there are many voices that avoid steroids due to side effects, so the development of new drugs is desired. In recent years, the evening immunosuppressant evening crolimus Although ointments have been used and are effective, there are also concerns about their side effects, and their use is restricted.
  • Japanese Patent Application Laid-Open No. 2000-250632 filed by the present applicant, discloses a cannabinoid receptor-regulating substance represented by the following general formula: A 2-oxoquinoline compound is disclosed.
  • the publication discloses the use of a cannapinoid receptor modulator as described in “Immunoimmune by detecting peripheral cell-type receptor, for example, receptor on macrophages (see Non-Patent Document 6). By regulating the reaction, it has anti-inflammatory effect, anti-allergic effect, and also has immunomodulatory effect, Development of agonists for peripheral cell-type receptors is underway.
  • pharmaceuticalals that selectively act on peripheral cell-type cannabinoid receptors may be safe drugs that do not show central effects such as hypothermia and dynamite, which are side effects. The development of peripheral cell receptor selective modulators is expected.
  • Patent Document 2 Japanese Patent Application Laid-Open No. 52-113139 (US Pat. No. 4,179,177) describes the effect of THC derivatives on the prevention of asthma attacks. (See Patent Document 2).
  • WO 01/642 12 discloses that a cannabinoid modulator, preferably a CB1 agonist, is used for the treatment of muscular diseases such as asthma and bronchitis (see Patent Document 4).
  • WO 01/95889 describes the anti-inflammatory effect of cannabidiol derivatives on arachidonic acid-induced ear edema (see Patent Document 5).
  • WO 01/895 58 9 describes a method for improving cough (ameliora te) by locally administering cannabinoid to regulate CB1 receptor present in peripheral cells and improve coughing (ameliora te). See Patent Document 6). '
  • WO 00Z166756 discloses a cannabinoid modulator and describes as indications skin diseases (such as atopic dermatitis), respiratory diseases (such as asthma), allergic rhinitis and the like. However, if the compound is CB1 selected And regulates the CB1 receptor present in peripheral cells (see Patent Document 7).
  • Patent Document 8 Japanese Patent Publication No. 8-5 04195 (W094 / 12466) discloses that a ligand for canna pinoy drecept is active in anti-inflammatory, anti-asthmatic, etc. (Patent Document 8).
  • Japanese Patent Application Laid-Open Nos. Hei 6-731014 (US Pat. No. 5,624,941) and Japanese Patent Laid-open No. Hei 7-324076 (US Pat. No. 5,546,920) disclose ligands for cannabinoid receptors. It is described that it can be used for the treatment of thymic disorders, asthma, immunomodulation and the like (see Patent Documents 9 and 10).
  • WO 01/98828 discloses that a compound of the ⁇ 6 tetrahydrocannabinol type can be used for the treatment of inflammation, asthma, lung diseases such as chronic obstructive pulmonary disease, autoimmune diseases and the like. Has been described. However, its action is due to the inhibition of N-methyl D-aspartate receptor and antioxidant activity, as well as inhibition of prostaglandin synthesis, inhibition of tumor necrosis factor production, inhibition of cyclooxygenase, and inhibition of nitric oxide production. (See Patent Document 11).
  • WO 02Z2 670 2 describes that a cannapinoid receptor modulator, particularly an agonist, is effective for asthma, allergy, skin diseases and the like (see Patent Document 12).
  • WO 01 Z87297 describes that a CB1 modulator is used for treating skin necrosis such as psoriasis (see Patent Document 13).
  • WO 02 42248 describes that a cannapinoid receptor binding agent, particularly CB1 agonist, is used for asthma, rhinitis, and inflammatory skin diseases (see Patent Document 14).
  • WO 02/476991 describes that cannabinoid receptor antagonist is used for treatment of inflammation and the like (see Patent Document 15). See).
  • Table 11-1-5 0 04 11 (WO 96Z1 839 91) states that CB2 modulators are used in the treatment of immune system disorders, chronic respiratory disorders (such as asthma), etc. It has been shown. It also describes that CB2 was found to be expressed in mast cells and non-immune cells (eg, cerebellar granules, cerebellum, and heart) (see Patent Document 16).
  • CB2 was found to be expressed in mast cells and non-immune cells (eg, cerebellar granules, cerebellum, and heart) (see Patent Document 16).
  • Table 1-111 (2016) states that CB2 modulators can be used for the treatment of autoimmune diseases, chronic inflammation, respiratory disorders (asthma, etc.), etc. It has been shown to be used (see Patent Document 17).
  • CB2 modulators can be used for pulmonary disorders (asthma, chronic bronchitis, etc.), allergic reactions (rhinitis, It has been shown to be used in the treatment of contact dermatitis, conjunctivitis, etc.) and immune system disorders (see Patent Document 18).
  • JP-A Japanese Patent Application Laid-Open (JP-A) No. 11-507073
  • US Pat. No. 6,134,648 discloses a CB2 agonist, and as an indication of the agonist, autoimmune disease, infectious disease, allergy. Diseases (specifically, acute hypersensitivity, asthma) are described. However, it is described that the action is selective for CB2, but suppresses cAMP production induced by forskolin (see Patent Document 19).
  • Table 2 00 0—5 0 2 0 8 0 (US 5 925 7678) has CB2 A compound having an affinity for a receptor is disclosed, and as an indication, an immune disease such as an allergic disease (immediate hypersensitivity or asthma) is described. However, it is described that the compound is a CB2 receptor antagonist (see Patent Document 20).
  • Table 2 0 1-5 0 8 7 9 9 ( ⁇ 098/3 1 2 2 7) uses CB 2 modulators, especially angiogonists, for the treatment of immune diseases, inflammation, etc. (See Patent Document 21).
  • Japanese Patent Application Laid-Open No. 2000-201 547 0 (US Pat. No. 6,262,112) states that the power nabinoid agonist, especially the CB1 agonist, contains allergic diseases, asthma, inflammatory and / or immunity. It is described as being effective in treating skin diseases of etiology. In addition, it is described that some of the compounds are effective for CB2 (see Patent Document 23).
  • WO99 / 57107 discloses that a CB2-selective modulator is used for anti-inflammatory and immunomodulation (see Patent Document 24).
  • WO 01/4083 discloses that CB2-selective modulators, especially agonists, contain inflammation, immune diseases such as atopic dermatitis, allergic dermatitis, asthma It is shown to be used for the treatment of breath and the like. However, it is described that the transformation suppresses the increase in cAMP. (See Patent Document 28).
  • WO 01/19807 describes that CB2 selective modulators, especially agonists, have anti-inflammatory and immunosuppressive effects. The test results are described. However, it is described that the compound suppresses cAMP elevation. (See Patent Document 29).
  • WO 01/29007 discloses that cannabinide preparations are used for anti-inflammatory, immune system regulation and the like. It is described that some of the compounds are angonists and others are agonists, and that the binding assay results also indicate a CB2-selective modulator (see Patent Document 30).
  • WO 01/28497 shows that CB2-selective modulators, especially agonists, have anti-inflammatory effects and the like (see Patent Document 31).
  • WO 01/32169 discloses that a CB2-selective agonist is used for treatment of anti-inflammatory, autoimmune diseases and the like (see Patent Document 32).
  • WO 01X 2832 29 indicates that a CB2 selective modulator is used for the treatment of anti-inflammatory, autoimmune diseases and the like (see Patent Document 33).
  • C WO 01Z28 No. 557 states that cannabinoid dressing modulators can be used in the treatment of anti-inflammatory, autoimmune diseases, etc., some of which are CB2-selective modulators. Certain test data is disclosed (see Patent Document 34). '
  • WO 01/32626 shows that CB2 antagonist is used for the treatment of anti-inflammatory, immune diseases and the like (see Patent Document 35).
  • WO 0 1/5 8 8 6 9 includes CB agonists, especially CB 2 agonists, It has been shown to be used for the treatment of respiratory diseases, especially asthma and bronchitis. It is also described that the agonist suppresses mucin production from lung epithelial cells (see Patent Document 36).
  • WO 0196633.0 discloses a compound that binds to CB2, and lists respiratory diseases, for example, inflammatory diseases such as asthma and bronchitis, as indications (Patent Document 37) reference).
  • WO 02/11035 describes that CB2 agonist is effective for treatment of asthma, nasal allergy, atopic dermatitis, autoimmune disease and the like.
  • test results showing that the compound suppresses cAMP production are shown (see Patent Document 38).
  • CB2 agonist contains immune system diseases such as psoriasis, allergic diseases such as hypersensitivity, asthma, allergic rhinitis, contact dermatitis, and inflammatory diseases such as arthritis. It is described as being effective for the treatment of such as (see Patent Document 39).
  • WO 02/58663 describes that a chinnavi-like compound, particularly a CB2-selective compound, is used for anti-inflammatory, regulation of the immune system and the like. It also describes that the compound is an agonist that suppresses cAMP production (see Patent Document 40).
  • WO 02/6 0447 describes CB1-selective modulators and CB2-selective modulators. It is also described that CB2 selective modulators, particularly antagonists, are used for anti-inflammatory, immune system regulation and the like (see Patent Document 41).
  • WO 02/53543 shows that CB2 affinity compounds are used as anti-inflammatory agents, immunosuppressants and the like.
  • the amount of cAMP produced by forskolin stimulation was measured, and several compounds showed agonist action, and a hedge erythrocyte-induced delayed hypersensitivity model was used. The test method is described (see Patent Document 42).
  • WO 02/7252 62 discloses that CB2 affinity compounds, especially agonists, are used as anti-inflammatory agents, immunosuppressants and the like.
  • the amount of cAMP produced by forskolin stimulation is measured, and several compounds exhibit agonist action, and a test method using a hedge erythrocyte-induced delayed type hypersensitivity reaction model is described (Patent Document 43). reference).
  • WO 02/27270 describes that a cannabinoid modulator, especially a compound that binds to CB2, is effective in treating atopic dermatitis, allergy, asthma, chronic obstructive pulmonary disease, bronchitis, etc. (See Patent Document 44).
  • WO 02/858666 describes that a CB2-selective agonist is effective for the treatment of pain (see Patent Document 45).
  • cannabinoid receptor modulators especially CB2-selective modulators, especially CB2-selective inverse agonists
  • cannabinoid receptor modulators especially CB2-selective modulators, especially CB2-selective inverse agonists
  • these modulators are effective for allergic dermatitis, atopic dermatitis, allergic irritability, immediate I-breathing response, late-onset asthmatic reaction, ⁇ road hypersensitivity. Absent.
  • DNFB-induced allergic skin induced by inflammation similar to atopic dermatitis was used as a disease model animal effective for determining an anti-allergic effect.
  • IgE-dependent allergic dermatitis mouse that induced triphasic (immediate phase, late phase, late phase) dermatitis (see Non-Patent Document 4). And so on.
  • These disease models have been used as models suitable for evaluating antiallergic effects, especially pharmacological effects of atopic dermatitis.
  • Patent Document 6 WO 01Z89589 (page 2, line 15 to page 4, line 2, FIG. 2B, 2C)
  • Patent Document 7 WO 01Z89589 (page 2, line 15 to page 4, line 2, FIG. 2B, 2C)
  • Patent Document 17 Special table 1 1 1 5 0.1 6 15 (page 16 from line 16 to line 21, page 52 from line 14 to page 54, line 7)
  • Tokiohira 1 1—5 0 7 9 3 7 page 13 from line 10 to line 22; page 66 to line 14 to page 67 to line 5)
  • Patent Document 38 O 0 2/1 0 1 3 5 (from page 71, line 10 to page 72, line 11)
  • the cannapinoid receptor modulator has not been successful as a pharmaceutical yet, and its effective use is being sought.
  • an object of the present invention is to provide a novel therapeutic agent for allergic diseases comprising a cannapinoid receptor monomodulator, particularly a modulator selective for peripheral cell-type cannabinoid receptors as an active ingredient.
  • the present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, have found that selective CB2 modulators can be used in allergic diseases such as energy asthma, atopic dermatitis, allergic rhinitis and allergic conjunctivitis.
  • the present inventors have demonstrated that the present invention works extremely effectively, and completed the present invention.
  • the medicament of the present invention is particularly effective as a therapeutic agent for allergic asthma and atopic dermatitis. This That is, the effect of the present invention far exceeds the effect suggested from the above-mentioned Japanese Patent Application Laid-Open No. 2000-25663 (W 00 0/40 562). It was amazing to do it myself.
  • a therapeutic agent for allergic diseases comprising a cannabinoid receptor modulator as an active ingredient.
  • the modulator of the cannapinoid receptor is a 2-oxoquinoline compound represented by the following general formula [I] or a pharmaceutically acceptable salt thereof.
  • the therapeutic agent for allergic disease according to (1) or (2).
  • R 3 and R 4 are the same or different and each represents a hydrogen atom or alkyl, R 5 represents a hydrogen atom or alkyl, t represents 0 or an integer of 1 to 2), and R 1 represents a hydrogen atom, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or cycloalkylalkyl.
  • Each group except for the hydrogen atom in the R 1 is an alkylamino, an amino, a hydroxyl group, an alkoxy, a carbonyl, an alkoxycarbonyl, an acyl, an acyloxy, an acylthio, a mercapto, an alkylthio, an alkylsulfinyl or an alkyl. May be frowned with sulfonyl, and each group except hydrogen atom and alkyl may be substituted with alkyl,
  • R 2 is a hydrogen atom, alkyl, —OR 6 (wherein R 6 represents a hydrogen atom, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or cycloalkylalkyl ), — NR 7 R 8 (wherein R 7 and R 8 are the same or different and are each a hydrogen atom, an alkyl, an alkenyl, an alkynyl, an acyl, an aryl, an arylalkyl, a heteroaryl, a heteroarylalkyl) Or R 7 and R 8 may form a heteroaryl together with an adjacent nitrogen atom.) Or one (CH 2 ) u .
  • R 9 is a hydrogen atom, an alkyl, a ⁇ alkenyl or alkynyl, the u and u 'are each independently an integer of 0 or 1 ⁇ optimum 2.
  • R 9 is a hydrogen atom, an alkyl, a ⁇ alkenyl or alkynyl
  • the u and u ' are each independently an integer of 0 or 1 ⁇ optimum 2.
  • R 2 Arukiruamino, Amino, hydroxyl, alkoxy, alkoxy force Ruponiru, Ashiru, Ashiruokishi, substituted Ashiruchio, mercapto Bok, alkyl Chio, alkylsulphinyl or alkylsulphonyl
  • R a represents a hydrogen atom or an alkyl
  • R Masorezore represents a hydrogen atom or an alkyl le
  • a 1 k a , A 1 k b and A 1 k c each independently represent an alkylene or an alkenylene, and the alkylene and the alkenylene are respectively a hydroxyl group, a carboxyl, an al.oxycarbonyl, an alkyl (the alkyl is a water group, may be substituted by alkoxy or alkylthio.) or single CONR ⁇ R 1 1 (wherein, either R 1 Q and R 1 1 represents a hydrogen atom or an alkyl the same or different, or R 1 Q and R 11 may be taken together with an adjacent nitrogen atom to form a heteroaryl.) R may be substituted with aryl, heteroaryl, cycloalkyl, benzene-fused cycloalkyl or
  • a and B each independently represent an oxygen atom, a nitrogen atom or a sulfur atom, and k represents an integer of 1 to 3
  • the aryl and heteroaryl are each substituted with a hydroxyl group.
  • the benzene condensed cycloalkyl may be completely substituted with a hydroxyl group or an alkoxy.
  • r, s, v and w each independently represent 0 or 1
  • Y and Z each independently represent a nitrogen atom, an oxygen atom or a sulfur atom
  • p and Q each independently represent 1 Shows an integer from 1 to 4.
  • W is -O-
  • R 1 is a hydrogen atom or alkyl (the alkyl is as defined above)
  • R 2 is - ⁇ R 6 (R 6 is as defined above).
  • R is aryl, heteroaryl or
  • the cannapinoid receptor modulator is a 2-oxoquinoline compound represented by the following general formula [I '] or a pharmaceutically acceptable salt thereof.
  • the agent for treating an allergic disease according to (1) or (2).
  • R 3 and R 4 are the same or different and each represent a hydrogen atom or an alkyl, R 5 represents a hydrogen atom or an alkyl, and t represents 0 or an integer of 1 to 2), and R 1 represents a hydrogen atom , alkyl, alkenyl, Arukieru, Ariru, Ari Ruarukiru, Heteroariru, heteroalkyl ⁇ reel alkyl, shows a cycloalkyl Le also ho cycloalkyl alkyl, said R 1 ⁇ this each dividing rather proviso that each hydrogen atom definitive, Arukiruamino, Amino, hydroxyl , Alkoxy, alkoxy, alkoxycarbonyl, acyl, acyloxy
  • R 1 0 ⁇ beauty R 1 1 represents a hydrogen atom or an alkyl the same or different, and May form a heteroaryl in which R 1 ° and R 11 together with an adjacent nitrogen atom.
  • R is aryl, heteroaryl, cycloalkyl, benzene-fused cycloalkyl or
  • a and B each independently represent an oxygen atom, a nitrogen atom or a sulfur atom, and k represents an integer of 1 to 3
  • the aryl and heteroaryl are each substituted with a hydroxyl group.
  • the benzene condensed cycloalkyl may be substituted with a hydroxyl group or an alkoxy.
  • R, s, v and w are each independently 0 or It indicates 1, respectively Y and Z are independently a nitrogen atom, an oxygen atom or a sulfur atom, p and q are shows the integer of 1 to 4 independently. ⁇ .
  • R 2 is a hydrogen atom
  • WR 1 is substituted at the j-position of 2-oxoquinoline
  • 1,2-dihydro-6,7-dimethoxy-2-oxo-1N— Excludes (phenylmethyl) -1-quinolinecarboxamide and N- (1,2-dihydro-6,7-dimethoxy-21-oxo-37quinolyl) benzamide.
  • X ′ is —CONRc— (A 1 ka a R).
  • R is a reel, heteroaryl or
  • substitution position of WR 1 is a j-position of the benzene ring
  • substitution position of R 2 is i-position of the benzene ring
  • 2-oxoquinoline compound is 7-methoxy-2-oxo-18-pentyloxy 1,2-dihydroquinoline-3-carboxylic acid
  • Cannapinoid receptor monomodulator is N- (benzo [1,3] dioxo-l-5-ylmethyl)-7-methoxy-2-oxo-l-8-pentyloxy 1,2-dihydroquinoline-3
  • the therapeutic agent for allergic disease according to (3) which is carboxamide or a pharmaceutically acceptable salt thereof.
  • Cannabinoid receptor modulators are SR 1445 28, HU-308, L-759663, L-17559656, L-7662842, PRS- 2 1 1 0 96, PRS—Selected from the group consisting of 2 1 1 3 35, PRS-2 1 1 3 5 9, AM 6 03, AM 17 0 3, AM 17 10 and AM 1221
  • the agent for treating an allergic disease according to (1) or (2).
  • the allergic disease is allergic dermatitis (1) to (1) 9)
  • the therapeutic agent for allergic disease according to any one of (1) to (25), which has a therapeutic effect in a DNFB-induced allergic dermatitis animal or an IgE-dependent allergic dermatitis animal.
  • Cannabinoid receptor modulator and “Cannapinoid receptor receptor modulator” are substances that regulate the biological activity of cannapinoid receptor receptor, or regulate the expression of cannabinoid receptor receptor. Substances, the former include agonists, angelic gonists, imperagonists, and other substances that enhance or reduce the sensitivity of cannapinoid receptors, and the latter include gene expression of cannapinoid receptors. Substances that enhance or suppress the same. Inverse agonists have the opposite effect of the receptor agonist. For example, from the viewpoint of cAMP levels at the cannapinoid receptor, it has been found that compound A increases cAMP levels as compared to that of cannapinoids, which suppresses the increase of cAMP.
  • Specific examples of the member are Compound A, SR144528, and AM630, preferably Compound A and SR144528.
  • Specific examples of cannabinoid dressing regulators include compounds represented by the general formula [I] described in Japanese Patent Application Laid-Open No. 2000-255632 (WO 00/40562).
  • it is a modulator that selectively acts on peripheral cell-type cannabinoid receptor, and is a compound described in JP-A-2000-256332 (WO 00/400 562). 0 2X 101 3 5 Compounds described, SR 144 45 28, AM 63 0, AM 122 1 etc.WO 01/28557 Compounds described, AM 1703 etc.
  • Compound A More preferred are Compound A, SR144528 and A630, more preferred are Compound A and SR144528, and most preferred is Compound A.
  • Allergic diseases include anaphylaxis, gastrointestinal allergies, allergic gastroenteropathy, allergic dermatitis, rash, rash such as cosmetic rash, rash, measles, atopic dermatitis, asthma, allergic asthma, atopic Asthma, allergic bronchopulmonary aspergillosis, hay fever, allergic rhinitis, allergic conjunctivitis, allergic granulomatous vasculitis, drug allergy, serum sickness, tuberculosis lesions, rejection after organ transplantation, tuberculosis lesions, Examples include, but are not limited to, rejection reactions after organ transplantation, and can be applied to any disease related to allergy.
  • allergic dermatitis More preferably, mention may be made of allergic dermatitis, atopic dermatitis, asthma, allergic asthma, atopic asthma, allergic rhinitis and allergic conjunctivitis. Particularly preferably, there may be mentioned allergic diseases relating to the skin or the respiratory tract, and more specific indications include allergic dermatitis, atopic dermatitis, allergic asthma and atopytic asthma.
  • Allergic dermatitis refers to dermatitis associated with an allergic reaction, and includes, for example, atopic dermatitis. It is distinguished from non-allergic dermatitis, such as wound dermatitis.
  • a drug that enhances the therapeutic effect by acting on the allergic reaction of atopic dermatitis is preferable.
  • the compound has an effect on a late-type reaction, a delayed-type reaction, or a delayed-type reaction and a delayed-type reaction of the allergic reaction. It is a therapeutic agent that has an effect on type response, late response and delayed response.
  • Allergic asthma refers to the allergic aspect of asthma symptoms and includes, for example, mixed asthma and atopic asthma. It is distinguished from non-allergic asthma such as aspirin asthma.
  • a drug which increases the therapeutic effect by acting on the allergic reaction of asthma is preferable.
  • the therapeutic agent has an effect on chronic bronchitis or airway hypersensitivity, and more preferably a therapeutic agent having an effect on chronic bronchitis and airway hypersensitivity.
  • the allergic reaction has an effect on a delayed type reaction, a delayed type reaction, or a delayed type reaction and a delayed type reaction. More preferably, it is a delayed type reaction in addition to an immediate type reaction. It is a delayed-type reaction or a therapeutic agent that has an effect on delayed-type and delayed-type reactions.
  • Antipruritic effect refers to the effect of reducing itching or eliminating itching, thereby reducing the pruritic response and reducing mental stress from itching. Not central effects, e.g. antihistamine, antisubstance
  • it preferably has an antipruritic effect on the above allergic diseases, especially atopic dermatitis.
  • the “cannobinoid receptor evening modulator” of the present invention can be a safe drug that does not have “immunosuppressive effects that cause side effects” such as steroids and immunosuppressants.
  • side effects such as steroids and immunosuppressants.
  • side effects include hyperkalemia, leukocyte and thrombocytopenia due to dysfunction of the kidney and spleen. For example, a decrease in spleen weight is an indicator.
  • drugs that can be orally administered are easier to handle than ointments and injections.
  • treatment means suppressing an allergic reaction or ameliorating the symptoms of an allergic disease, which may occur. This includes preventing allergic reactions or allergic diseases and preventing their exacerbation.
  • FIG. 1 is a graph showing the effect of a test compound on ear swelling after the fourth antigen application in mouse DNFB-induced allergic dermatitis.
  • the vertical axis represents “increase in pinna thickness (X10_1 ⁇ 2m)” of mice before and after administration of the test compound. From the left, sham treatment, vehicle (vehicle only 10 mg / kg orally), prednisolone (orally administered 1, 2, and 5 mg / kg as positive control), compound A (0.1, 1, 10 mg / kg) Is given orally.).
  • FIG. 2 is a graph showing the effect of a test compound on pinna swelling after the fifth antigen application in mouse DNFB-induced allergic dermatitis.
  • the vertical axis represents the "increase in ear thickness (X 1 0- 2 mm)" of the mouse before and after the test compound administration. From the left, sham treatment, vehicle (vehicle only 10 mg / kg orally), prednisolone (orally administered 1, 2, and 5 mg / kg as positive control), compound A (0.1, 1, 10 mg / kg) Is given orally.).
  • FIG. 3 is a graph showing the effect of a test compound on spleen wet weight in a DNFB-induced allergic allergic dermatitis model.
  • the vertical axis represents the spleen wet weight (mg). From the left, sham treatment, vehicle (vehicle only 10 mg / kg orally), prednisolone (orally administered 1, 2, and 5 mg / kg as positive control), compound A (0.1, 1, 10 mg / kg) Is given orally.).
  • FIG. 4 is a graph showing the effect of a test compound on ear swelling in the immediate phase (one hour after antigen application) in mouse IgE-dependent allergic dermatitis reaction.
  • the vertical axis represents the “increase in the thickness of the pinna (XI 0- ⁇ m)” of the mouse before and after the administration of the test compound.
  • the solvent solvent only 10 mg / k g oral administration.
  • the solvent Orally 10 mg / kg as a positive control.
  • Ketotifen fumarate Plan The results for lucast hydrate (30fflg / kg orally as a positive control) and Compound A (10mg / kg orally) are shown.
  • FIG. 5 is a graph showing the effect of a test compound on ear swelling in the late phase (24 hours after application of the antigen) in mouse IgE-dependent allergic dermatitis reaction.
  • the vertical axis indicates the increase in the thickness of the pinna of the mouse before and after the administration of the test compound (X I).
  • 0_ represents a 2 mm) ". From the left, respectively, a solvent (vehicle only 10 mg / kg is orally administered), ketotifen fumarate (orally administered 10 mg / kg as a positive control), and pranlukast hydrate (orally administered 30 mg / kg as a positive control) The results for Compound A (10 mg / kg, administered orally) are shown.
  • FIG. 6 is a graph showing the effect of a test compound on ear swelling in the late late phase (8 days after antigen application) in a mouse IgE-dependent allergic dermatitis reaction.
  • the vertical axis indicates the increase in the thickness of the pinna of the mouse before and after the administration of the test compound (X I).
  • 0_ represents a 2 mm) ". From the left, respectively, a solvent (vehicle only 10 mg / kg is orally administered), ketotifen fumarate (orally administered 10 mg / kg as a positive control), and pranlukast hydrate (orally administered 30 mg / kg as a positive control) The results for Compound A (10 mg / kg, administered orally) are shown.
  • FIG. 7 is a graph showing the influence of the administration period of the test compound on the mouse IgE-dependent allergic allergic dermatitis reaction.
  • the vertical axis represents the "increase in ear thickness (X 1 0- 2 mm)" in our Keru mice before and after the test compound administration.
  • 0-8 indicates the administration period from the day of antigen application to 8 days after. From left to right each solvent (solvent only).
  • Compound A oral administration of 10 mg / kg for 9, 8, 7, 5, 3 days.
  • FIG. 8 is a graph showing the effect of a test compound on respiratory resistance in immediate asthma (one minute after antigen induction) in guinea pig antigen-induced asthma.
  • the vertical axis indicates the rate of increase (%) in airway resistance (sRaw). From the left, sham treatment, vehicle (vehicle only 10 mg / kg orally), compound A (10, 30, 100 mg / kg orally), The results for pranlukast (orally administered 30 mg / kg as a positive control) and prednisolone (orally administered 30 mg / kg as a positive control) are shown.
  • FIG. 9 is a graph showing the effect of test compounds on respiratory resistance in late-onset asthma (4 to 8 hours after antigen induction) in guinea pig antigen-induced asthma. And the vertical axis represents the AU C 4 _ 8h r (% 'hr). The AUC 4 _ -8 hr, a rate of increase in the airway resistance after the antigen induction 4-8 hours (sRaw) (area under the curve ratio).
  • FIG. 10 is a graph showing the effect of test compounds on guinea pig airway response. The vertical axis is PC l fl . ACli (mg / ml) is shown.
  • PC 1 () () ACh is the concentration of acetylcholine required to increase airway resistance (sRaw) after acetylcholine inhalation by 100% from sRaw after saline inhalation.
  • vehicle vehicle only 10 mg / kg orally
  • Compound A 10, 30, 100 mg / kg orally
  • pranlukast (30 mg / kg orally as a positive control
  • prednisolone (30 mg / kg orally as a positive control).
  • FIG. 11 is a diagram showing the effect of a test compound on leukotriene production from human basophils.
  • the vertical axis shows the amount of leukotriene (C4 / D4 / E4) (pg / mL), and the horizontal axis shows the amount of anti-IgE antibody (g / mL).
  • FIG. 12 shows the effect of the test compound on leukotriene production from rat mast cells.
  • the vertical axis shows the amount of leukotriene (C4 / D4 / E4) (pg / mL;), and the horizontal axis shows the amount of DNP-BSA (ng / mL).
  • Figure 13 shows the effect of the test compound on ear swelling in the late late phase (8 days after antigen application) in mouse IgE-dependent allergic dermatitis reaction. You.
  • the vertical axis represents the “thickening of the auricle (X10 ⁇ m)” of the mouse before and after the administration of the test compound.
  • the unsensitized group, the sensitized group, HU-308 (10, 50 mg / kg orally), Compound A (0.1, 1, 10 mg / kg orally), prednisolone ( 5 mg / kg was orally administered as a positive control.)
  • the unsensitized group, the sensitized group, SR144528 (0.1, 1, 10 mg / kg orally), Compound A (10 mg / kg orally), prednisolone (5 mg / kg of oral administration).
  • FIG. 14 is a graph showing the effect of the test compound on spleen and thymus wet weight in the late late phase (8 days after antigen application) in mouse IgE-dependent allergic dermatitis reaction.
  • the vertical axis in the upper figure represents the spleen wet weight (mg).
  • the vertical axis in the figure below represents the thymus wet weight (mg). From the left, the unsensitized group, the sensitized group, HU-308 (10, 50 mg / kg orally), Compound A (0.1, 1, 10 mg / kg orally), prednisolone (5 mg / kg) Oral administration.).
  • FIG. 15 shows the effect of the test compound on the spleen and thymus wet weight in the late onset phase (8 days after antigen application) in mouse IgE-dependent allergic dermatitis reaction.
  • the vertical axis in the upper figure represents the spleen wet weight (mg).
  • the vertical axis in the figure below represents the thymus wet weight (mg). From the left, the non-sensitized group, the sensitized group, SR14 4528 (0.1, 1, 10 mg / kg orally), Compound A (10 mg / kg orally), prednisolone (5 mg / kg orally), respectively. The result is shown.
  • FIG. 16 shows the time course of auricular swelling induced by the test compound in mouse IgE-dependent allergic dermatitis reaction.
  • the vertical axis represents the "thickening of auricle (X10- 2 mm)" of the mouse before and after the test compound administration. From left, time after compound application is shown.
  • Mean Sat Standard error, (n 6)
  • Figure 17 shows auricular edema induced by 2-arachidonylglycerol ether (2-AG-E) in mouse IgE-dependent allergic dermatitis response
  • FIG. 16 shows the time course of auricular swelling induced by the test compound in mouse IgE-dependent allergic dermatitis reaction.
  • the vertical axis represents the "thickening of auricle (X10- 2 mm)" of the mouse before and after the test compound administration. From left, time after compound application is shown.
  • Mean Sat Standard error, (n 6)
  • Figure 17 shows auricular edema induced by 2-arachidony
  • FIG. 4 is a graph showing the effect of compound A on The vertical axis represents AUC (days 0 to 8).
  • vehicle vehicle only 10 mg / kg was orally administered
  • Compound A 0.01, 0.1, 1, and 10 mg / kg were orally administered
  • the compound of the present invention when used as a pharmaceutical composition, it can be administered in the form of a formulation by a known pharmaceutical method, in addition to directly administering the compound itself to a patient.
  • a known pharmaceutical method for example, if necessary, in addition to Formulation Examples 1 (forced capsules) and 2 (tablets), microcapsules, soft and hard capsules, pills, solutions, powders, granules, fine granules, film cores Pills, pellets, troches, sublinguals, chewing agents, buccal agents, pastes, syrups, suspensions, elixirs, emulsions, eye drops, ear drops, coatings, ointments, plasters, Sterile solution, suspension, or milk in poultice, TTS, lotion, inhalant, or aerosol, orally or parenterally, or with water or other physiologically acceptable liquids
  • the cloudy solution can be used parenterally in the form of injections.
  • parenteral administration examples include topical solutions containing one or more active substances, formulated in a conventional manner, suppositories, pessaries, emulsion foams for enteral administration Etc. I will. Also, for example, a pharmacologically acceptable carrier or medium, specifically, sterile water or physiological saline, vegetable oil, solvent, base, emulsifier, suspending agent, surfactant, stabilizer, flavor, fragrance, etc.
  • Excipients Excipients, vehicles, preservatives, binders, diluents, isotonic agents, analgesics, bulking agents, disintegrants, buffers, coatings, lubricants, coloring agents, sweeteners,
  • the formulation may be made by appropriately combining with a thickener, flavoring agent, solubilizing agent or other additive, etc., and mixing in the unit dose form required for accepted pharmaceutical practice.
  • Additives that can be incorporated into tablets and capsules include, for example, binders such as gelatin, corn starch, tragacanth gum, acacia, excipients such as crystalline cellulose, corn starch, gelatin, and arginic acid. Suitable leavening agents, lubricating agents such as magnesium stearate, sweetening agents such as sucrose, lactose or saccharin, and flavoring agents such as peppermint, cocoa oil or cherry are used.
  • the preparation unit form is a capsule, the above materials may further contain a liquid carrier such as oil and fat.
  • Sterile compositions for injection can be formulated according to normal pharmaceutical practice using a vehicle such as distilled water for injection.
  • Aqueous solutions for injection include, for example, saline, isotonic solutions containing dextrose and other adjuvants, such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride. It may be used in combination with an agent such as alcohol, specifically ethanol, polyalcohol such as propylene glycol, polyethylene glycol, a nonionic surfactant such as polysorbate 80 (TM) or HC0-50.
  • an agent such as alcohol, specifically ethanol, polyalcohol such as propylene glycol, polyethylene glycol, a nonionic surfactant such as polysorbate 80 (TM) or HC0-50.
  • oily liquid examples include sesame oil and soybean oil, which may be used in combination with benzyl benzoate or benzyl alcohol as a solubilizing agent.
  • buffers such as phosphate buffers, sodium acetate buffers, soothing agents, such as hydrochloric acid It may be blended with rockines, stabilizers such as benzyl alcohol, phenol, and antioxidants.
  • the prepared injection is usually filled in an appropriate ampoule.
  • the dosage may vary depending on the type and degree of the disease, the compound to be administered and the route of administration, the age, sex, weight, etc. of the patient.
  • oral administration usually 0.1 to 1000 mg, preferably 1 to 300 mg of Compound A per adult day is administered in one or several divided doses.
  • the compound of the present invention can also be applied as a veterinary medicine.
  • Pharmacological test
  • Atopic dermatitis is considered to be a complex intertwining of type I and type IV allergic reactions, and a model in which type I and type IV all occur alone or in combination is useful.
  • This model is a model in which contact dermatitis with an increase in IgE antibody titer, that is, inflammation similar to atopic dermatitis, is induced by repeatedly eliciting mice after sensitization with anti- ⁇ (J Allergy Clin. Immunol., 100 (6Pt2), 39-44, Dec. 1997). This model is thought to cause inflammation by delayed allergic reaction by T cells and delayed allergic reaction by mast cells. At the same time, the spleen weight was measured in this test to examine the systemic immunosuppressive effect of the test compound.
  • Test method '.' • Preparation of test compound
  • MC Methylcellulose
  • test compound A compound was synthesized according to Examples 3-5 of JP-A-2000-2566323. A predetermined amount of compound A was suspended in the above solvent to give a lmg / mL suspension. Further dilutions were made into 0.1 mg / mL and 0.01 mg / mL suspensions. Similarly, prednisolone (Sigma) was prepared as a positive control at 0.5 mg / mL, 0.2 mg / mL, and 0.1 mg / mL. Prednisolone is one of the corticosteroids that is effective in treating atopic dermatitis. • Preparation and application of antigen
  • Antigen application The above antigen was applied to the front and back of both ears of a 9-week-old female BALBZc mouse (manufactured by SLC) at a rate of 25 / zL once a week for a total of 5 times.
  • test compound was administered 10 mL / kg once a day for a total of 15 times a day.
  • the antigen was administered 1 hour before the antigen application and 23 hours after the antigen application the day after the antigen application.
  • the thickness of the pinna was measured using a dial thickness gauge (Yamae Kikai), and the difference was used as an index of swelling.
  • the measurement results for the fourth and fifth antigen applications, together with the results for the positive control, are shown in FIGS. 1 and 2.
  • Compound A significantly suppressed swelling of the pinna in this allergic allergic dermatitis model.
  • the effect was shown at the start of administration after the third antigen application. At that time, the decrease in spleen weight observed for prednisolone was not shown.
  • This model is a model in which mice are passively sensitized with IgE and then repeatedly challenged with antigen to induce triphasic (immediate, late, late) dermatitis (Pharmaco l ogy, 60 (2), 97-104, Feb. 2000). These reactions are considered to reflect some of the symptoms of atopic dermatitis, since the involvement of mast cells and T cells and the infiltration of eosinophils at the inflamed area were confirmed.
  • MC was dissolved in distilled water to obtain a 0.5% MC aqueous solution.
  • test compound A predetermined amount of compound A was suspended in the above-mentioned solvent to prepare a lmg / mL suspension.
  • ketotifen fumarate (Sigma) 1 mg / mL and pranlukast hydrate (trade name extracted from Onon Tablets (Ono Pharmaceutical Co., Ltd.)) 3 ig / mL were prepared as described above.
  • Branlukast hydrate is used as a leukotriene inhibitor, as a therapeutic agent for asthma and allergic rhinitis
  • ketotifen fumarate is used as a chemical media release inhibitor for asthma, allergic rhinitis, eczema , Dermatitis, measles, pruritus cutis, Used for allergic conjunctivitis.
  • Anti-DNP IgE (antibody against DNP, yamasa soy sauce) was adjusted to 15 S / mL with physiological saline, and administered to 9-week-old female BALBZc mice (manufactured by SLC) via the tail vein of 0.2 mL.
  • Antigen application Twenty-four hours after the administration of the anti-DNP IgE, 25 L of the antigen was applied to the front and back of both auricles.
  • mice From the day of antigen application to day 8 after antigen application, 10 ml / kg was orally administered at a rate of once a day for a total of 9 times.
  • the other mice were orally administered 10 ml / kg once a day for a total of 8, from 1 day after the antigen application to 8 days after the antigen application.
  • other mice were orally administered 10 ml / kg at a rate of 7, 5, 3 times and once a day, respectively, from 2, 4 and 6 days after antigen application to 8 days after antigen application.
  • 10 ml / kg of the solvent alone was orally administered once a day instead of the test compound.
  • the antigen was administered one hour before the antigen application day and one hour before the measurement of the pinna thickness on the eighth day after the antigen application.
  • the thickness of the pinna was measured using a dial thickness gauge (Yamae Kikai), and the difference between the value before the antigen application and the value at each time was measured. was used as an index of swelling.
  • FIGS. 4 to 6 show the respective measurement results. Also, the timing of application start for the swelling suppression effect 8 days after antigen application 3806
  • Fig. 7 shows the effect of -55-.
  • Compound A significantly increased the immediate phase (1 hour after application), the delayed phase (24 hours after application), and the late delayed phase (8 days after application) in this IgE-dependent dermatitis model.
  • the swelling of the pinna was suppressed.
  • the effect of Compound A in the late-onset phase was also observed when dosing was started after the onset of the late-onset phase.
  • a predetermined amount of Compound A was suspended in a 0.5% MC aqueous solution to a concentration of 60 mg / mL.
  • the test compounds were further diluted and prepared at 20, 6, and 2 mg / mL before use.
  • pranlukast hydrate extracted from Onon Tablets (Ono Pharmaceutical Co., Ltd.)
  • prednisolone Sigma
  • Sensitization A 6-week-old male Hartley-type guinea pig (Kudo Co., Ltd.) was treated with 1% 0VA (ovalbumin, Sigma) -containing physiological saline for 1 day using an ultrasonic nebulizer (NE-U12, OMRON). Inhalation was continued for 10 minutes for 8 consecutive days.
  • 0VA ovalbumin, Sigma
  • Antigen challenge One week after the final sensitization, 2% 0VA was similarly inhaled for 5 minutes. 0 VA before and 24 hours before the onset of metyrapone saline (Aldriclu 10 mg / kg) intravenously, and 30 min before OVA induction, pyrilamine-containing saline (Sigma, 10 mg / kg) intraperitoneally. was administered.
  • pranlukast hydrate was administered 1 hour before induction, and prednisolone was administered 16 hours and 2 hours before induction. The animals were fasted 16 to 18 hours before oral administration.
  • sRaw specific airway resistance
  • the increase rate of sRaw 1 minute after OVA induction is shown in FIG. 8, and the increase rate of sRaw 4 to 8 hours after induction (area under the curve: AUC4-8hr) is shown in FIG.
  • ACh physiological saline and acetylcholine
  • compound A is an antigen-induced immediate asthmatic response (antigen-induced TJP02 / 13806
  • LTs Leukotrienes
  • the basophils were adjusted to 2.5 ⁇ 10 6 cells / mL with Tyrode's solution and added to 10 g / mL recombinant human IL-3 (Genzyrae / Techne) to a final concentration of lOOng / mL.
  • Anti-human IgE antibody diluted to 1, 3, 10, 30, or 100 g / mL with Tyrode's solution was added at ⁇ / iL / well, and incubated at 37 ° C and 5% C02 for 30 minutes (final concentrations were respectively 0.1, 0.3, 1, 3,
  • the suspension was centrifuged at 3000 rpm for 5 min at 4 and the supernatant was collected at 80 L / well.
  • the amount of LTs in the supernatant was measured according to the manufacturer's protocol of the LTs EIA Kit (Amersham pharmacia). Samples were diluted 3 and 24 times with Tyrode's solution and measured. Figure 11 shows the measurement results.
  • Compound A showed an inhibitory effect on leukotriene (C4 / D4 / E4) production from human basophils.
  • a predetermined amount of compound A was diluted with DMS0 and adjusted to 3, 1, 0.3, O. lmM (100% DMS0 solution).
  • E-MEM EAGLE-MEM, Niken Institute for Biological Research
  • 100 to 1 M 100 to 1 M, respectively (1% DMS0 solution).
  • E-MEM EAGLE-MEM, Niken Institute for Biological Research
  • ImM PIPES (Dojindo Laboratories), 1mM NaCK 0.5mM KC1, 0.06mM MgC12, 0. ImM CaC12, 0.55mM Glucose, 0.1% BSA (Bovine Serum Albumin, Sig ma) were prepared in purified water, and pH was adjusted with NaOH. It was 7.4.
  • lmg / niL anti-DNP IgE (monoclonal mouse anti-DNP-IgE, Yamasa) was diluted 1000-fold with the above PIPES Buffer to prepare a 1 g / mL solution.
  • E-MEM medium E-MEM medium containing inactivated 10% FCS (Fetal Calf Serum, Morgate Biotech), lOOunits / mL Penicillin, 100 ng / mL Streptomycin (GIBC0 as Penici 11 in / Streptomyc in).
  • FCS Fetal Calf Serum, Morgate Biotech
  • lOOunits / mL Penicillin 100 ng / mL Streptomycin (GIBC0 as Penici 11 in / Streptomyc in).
  • rat mast cell line RBL- 2H3 the Human Science lxl0 6 cells / mL / tub e
  • centrifugal washing with the culture medium, resuspended in the same medium, and cultured for 3 days in 75 cm 2 flasks (Falcon 353136).
  • the cells were further cultured in a 225 cm 2 flask (CORNING 43 1082) for 2 days.
  • the cells were rinsed with HBSS and then removed with Trypsin-EDTA. After collecting the cells, the cells were washed by centrifugation in the above medium, and resuspended in the same medium.
  • the cells were prepared at 2 ⁇ 10 5 cells / mL, seeded at 250 L / well on a 96-well flat bottom culture plate (Falcon 3072), and cultured at 5% CO 2 at 37 ° C. for 20 hours. 13806
  • Fig. 12 shows the measurement results.
  • compound A showed an inhibitory effect on leukotriene (C4 / D4 / E4) production from a rat mast cell line.
  • CB2 inverse agonist The effects of CB2 inverse agonist and CB2 agonist were investigated using a triphasic dermatitis model induced by antigen after passive sensitization of mice with IgE.
  • MC was dissolved in distilled water to obtain a 0.5% MC aqueous solution.
  • test compound A predetermined amount of compound A was suspended in the above-mentioned solvent to prepare 0.01, 0.1, and 1 mg / mL suspensions.
  • prednisolone Sigma
  • 1.5 mg / mL of HU-308, a CB2-specific agonist, and a CB2-specific inverse agonist were used as comparative controls.
  • 0.01, 0.1 and 1 mg / mL of SR144528 were prepared as MC suspension as above.
  • Anti-DNP IgE (antibody to DNP, yamasa soy sauce) was adjusted to 15 g / mL with physiological saline, and 0.2 mL of the solution was administered to mice via the tail vein.
  • Antigen application Twenty-four hours after the administration of the anti-DNP IgE, 25 zL of the antigen was applied to the front and back of both ears.
  • the thickness of the pinna was measured using a dial thickness gauge (Yamae Kikai), and the difference between the value before the antigen application and the value at each time was used as an index of swelling.
  • Figure 13 shows the measurement results.
  • Compound A significantly suppressed auricular swelling in the late late phase (8 days after application) at all doses of 0.1, 1, and 10 mg / kg.
  • SR144528 a CB2 inverse agonist
  • HU-308 a CB2 agonist
  • HU-308 showed no efficacy at either 10 or 50 mg / kg.
  • prednisolone significantly suppressed the weight of both organs, whereas no obvious change was observed in Compound A and SR144528.
  • Animals receiving HU-308 showed a significant decrease in spleen weight.
  • the synthesized 2-AG-E and HU-308 were adjusted to 10% (w / v) and 10% (/ v), respectively, and AA (Sigma) was adjusted to 1.25% (w / v) with acetone. It was prepared at the time of use and applied to the front and back of the left pinna by 10/2 L each.
  • MC was dissolved in distilled water to obtain a 0.5% MC aqueous solution.
  • Preparation of Compound A A predetermined amount of Compound A was suspended in the above-mentioned solvent to prepare 0.001, 0.01, 0.1 and 1 mg / mL suspensions.
  • the vehicle or compound A was orally administered at 10 mL / kg, and 1 hour later, 10% (w / v) of 2-AG-E was applied to the front and back of the left auricle by 10 L / L respectively.
  • the thickness of the pinna was measured using a dial thickness gauge (Yamaeki) before, 1, 3, 6, 9, 24 hours and 2, 3, 8 days after application of the test substance. The difference between the value before application and the value at each time was used as an index of swelling.
  • the value calculated from the area under the curve obtained from the time course of pinna swelling up to 8 days after the application of 2-AG-E was used. Figures 16 and 17 show the measurement results.
  • Compound A inhibited the swelling of the auricle caused by 10% 2-AG-E application in a dose-dependent manner, and showed a significant effect at 1 and 10 mg / kg.
  • NC mice are used as animal models for atopic dermatitis. No dermatitis-like behavior is observed when bred in an environment that controls microorganisms in the air (under an SPF environment). However, when bred in a normal environment (under a CO nventional environment), swelling and movement begin to be observed with the onset of dermatitis around the 8th week, and the symptoms are known to be chronic (J. Dermatol). Sci., 25, 20-28, 2001).
  • MC was dissolved in tap water to obtain a 0.5% (w / v) MC aqueous solution.
  • test compound A predetermined amount of compound A was suspended in the above solvent to prepare a lmg AiL, 0.1 mg / mL suspension.
  • betamethasone valerate Sigma
  • Takuguchi limus hydrate Extracted from Prograf (Fujisawa Pharmaceutical)
  • Benzomethasone valerate is one of the adrenocortical steroids that is effective in the treatment of atopic dermatitis
  • Takuguchi limus hydrate is a therapeutic agent for atopic dermatitis known as an immunosuppressant as described above. It is. • Animal care and selection
  • mice Four-week-old male NC / Jic mice (CLEA Japan) were bred for 12 days in the same cage as mice (A) that developed severe skin lesions infected with rodent time (Myobia musculi), and then bred.
  • Rearing conditions Temperature 22 ⁇ 2 ° C, Humidity 55 ⁇ 10%, Illumination time 8: 00-20: 00, Feeding Solid feed CA-1 (Clear Japan), drinking water, drinking water, and tap water . From 10 days before the start of the experiment, for 2 or 3 days from the start of the experiment, the number of push movements (20 minutes, once a day) by the hind limbs of the mouse was visually counted, and the punching movement was measured from among the measured multiple mice. The mouse was selected and used several times more than 50 times a day on average.
  • mice were orally administered once a day at 10 mL / kg for three weeks. •Test method
  • the behavior of the mouse was photographed with a video camera in an unmanned environment, and the movement of the hind limb during one hour was counted.
  • the mouse usually shows several movements per second, but this series of movements was counted as one movement, and all the movements were counted without distinction. Measurements were taken on the first day of administration, 1, 3, 6, 10, 13, 17, and 20 days later. Fig. 18 shows the results together with the positive control.
  • Inverse agonists were found to be effective as therapeutic agents for allergic diseases.
  • cannabinoid receptor modulators especially compound A and CB2-selective inverse agonists such as SR144528, are currently intractable with significant effects only with the steroid and immunosuppressive drug chlorimus hydrate. It is effective for allergic dermatitis, especially for atopic dermatitis.
  • a cannabinoid receptor modulator in particular, a CB2-selective inverse agonist such as compound A, was found to reduce the predominant movements attributed to allergic reactions in a mouse pruritus response test. Furthermore, it could be a safe drug that does not show systemic immunosuppression, and its availability as an oral drug was also shown.
  • Compound A and SR144528 are known to selectively and strongly act on cannapinoid receptors, particularly CB2 receptors.
  • CB2 selective agonist H U-308 and cannabinoid endogenous ligand 2-AG derivative, 2-AG-E showed no anti-allergic activity, and 2-AG-E caused an allergic reaction.
  • the therapeutic effect on allergic diseases such as Compound A and SR144528 It is thought to be due to the effect on the nabinoid receptor, especially as a drug with a mechanism of action different from that of existing drugs for treating allergic diseases.
  • the cannabinoid receptor modulator is effective as a therapeutic agent for allergic diseases such as asthma and atopic dermatitis.
  • modulators that selectively act on peripheral cell-type cannabinoid dressing and those that act as impergonists are effective for chronic 'refractory allergic diseases, which are less effective with existing therapeutic agents for allergic diseases. Yes, and can be a safe drug.

Abstract

L'invention concerne des remèdes pour affections allergiques, qui renferment des régulateurs de récepteur cannabinoïde, en particulier les régulateurs agissant sélectivement sur les récepteurs cannabinoïdes du type cellules périphériques, comme le composé N-(benzo[1,3]dioxol-5-ylméthyl)-7-méthoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-caroxamide, y compris les sels pharmaceutiquement acceptables de ce composé. Les remèdes considérés sont efficaces pour lutter contre les affections allergiques réfractaires (par exemple, asthme et dermatite atopique).
PCT/JP2002/013806 2001-12-27 2002-12-27 Remedes pour affections allergiques WO2003061699A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/375,057 US20030232855A1 (en) 2001-12-27 2003-02-28 Therapeutic agent for allergic disease
US10/734,577 US20040171613A1 (en) 2001-12-27 2003-12-15 Therapeutic agent for non-immediate type allergic diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001396981 2001-12-27
JP2001-396981 2001-12-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/375,057 Continuation US20030232855A1 (en) 2001-12-27 2003-02-28 Therapeutic agent for allergic disease

Publications (1)

Publication Number Publication Date
WO2003061699A1 true WO2003061699A1 (fr) 2003-07-31

Family

ID=27602910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/013806 WO2003061699A1 (fr) 2001-12-27 2002-12-27 Remedes pour affections allergiques

Country Status (2)

Country Link
US (1) US20030232855A1 (fr)
WO (1) WO2003061699A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
PT1477186E (pt) * 2002-02-19 2010-02-11 Shionogi & Co Antipruriginosos
WO2005016351A1 (fr) * 2003-08-18 2005-02-24 Shionogi & Co., Ltd. Nouvelle utilisation d'un agoniste du recepteur cannabinoide
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
TWI360539B (en) * 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2008113006A1 (fr) * 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Procédés d'utilisation de composés à base de quinolinone dans le traitement des maladies ou des affections associées aux canaux sodiques
IE20070928A1 (en) * 2007-12-21 2009-09-30 Giuliani Int Ltd Multi target ligands
US11045454B2 (en) 2018-12-06 2021-06-29 Palo Alto Investors LP Methods of treating food allergy conditions

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002248A1 (fr) * 1994-07-15 1996-02-01 Eli Lilly And Company Antagonistes des recepteurs des cannabinoides
WO1996025397A1 (fr) * 1995-02-15 1996-08-22 Merck Frosst Canada Inc. Derives d'indole ayant une affinite pour le recepteur cannabinoide
WO1997000860A1 (fr) * 1995-06-21 1997-01-09 Sanofi Composes agonistes du recepteur cb¿2?
WO1997021682A1 (fr) * 1995-12-08 1997-06-19 Sanofi Derives de 3-pyrazolecarboxamide avec une affinite pour le recepteur des cannabinoides
WO1998037061A1 (fr) * 1997-02-21 1998-08-27 Bayer Aktiengesellschaft Arylsulfonamides et leurs analogues, et procedes d'utilisation desdites substances pour traiter les maladies neurodegeneratives
EP0887340A1 (fr) * 1996-02-06 1998-12-30 Japan Tobacco Inc. Composes chimiques et utilisation pharmaceutique
WO1999002499A1 (fr) * 1997-07-11 1999-01-21 Japan Tobacco Inc. Composes quinoline et utilisations de ceux-ci en medecine
WO2000010967A1 (fr) * 1998-08-19 2000-03-02 Bayer Aktiengesellschaft Nouveaux arylsulfonamides et leurs analogues
WO2000010968A2 (fr) * 1998-08-19 2000-03-02 Bayer Aktiengesellschaft Nouveaux esters d'aminoacides d'arylsulfonamides et leurs analogues
WO2000016756A2 (fr) * 1998-09-24 2000-03-30 Innovet Italia S.R.L. Derives de n-acylvanillinamide capables d'activer des recepteurs peripheriques de cannabinoides
WO2001004083A1 (fr) * 1999-07-07 2001-01-18 Innovet Italia S.R.L. Derives covalents d'alkanolamides d'acide monocarboxylique et dicarboxylique agissant de maniere fonctionnelle sur le recepteur cannabinoide cb2
WO2001028497A2 (fr) * 1999-10-18 2001-04-26 University Of Connecticut Nouveaux agonistes de cannabinoides bicycliques destines au recepteur de cannabinoides
WO2001028329A1 (fr) * 1999-10-18 2001-04-26 University Of Connecticut Ligands selectifs de recepteurs (cb2) de cannabinoides peripheriques
WO2001028557A1 (fr) * 1999-10-18 2001-04-26 University Of Connecticut Derives indoliques cannabimimetiques
WO2001032169A1 (fr) * 1999-10-31 2001-05-10 Yissum Research Development Company Of The Hebrew University Agonistes specifiques pour le recepteur peripherique de cannabinoides
EP1142877A1 (fr) * 1999-01-08 2001-10-10 Japan Tobacco Inc. Composes de 2-oxoquinoline et leurs utilisations medicinales
WO2002010135A1 (fr) * 2000-08-01 2002-02-07 Ono Pharmaceutical Co., Ltd. Composes derives de 3,4-dihydroisoquinoline et medicaments contenant ces composes comme principe actif
WO2002026702A1 (fr) * 2000-09-26 2002-04-04 Bayer Aktiengesellschaft Sulfonates d'alcane de phenoxyphenyle
WO2002062750A1 (fr) * 2001-02-08 2002-08-15 Schering Corporation Ligands des recepteurs cannabinoides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605906A (en) * 1995-03-24 1997-02-25 Merck Frosst Canada, Inc. Cannabinoid receptor agonists

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002248A1 (fr) * 1994-07-15 1996-02-01 Eli Lilly And Company Antagonistes des recepteurs des cannabinoides
WO1996025397A1 (fr) * 1995-02-15 1996-08-22 Merck Frosst Canada Inc. Derives d'indole ayant une affinite pour le recepteur cannabinoide
WO1997000860A1 (fr) * 1995-06-21 1997-01-09 Sanofi Composes agonistes du recepteur cb¿2?
WO1997021682A1 (fr) * 1995-12-08 1997-06-19 Sanofi Derives de 3-pyrazolecarboxamide avec une affinite pour le recepteur des cannabinoides
EP0887340A1 (fr) * 1996-02-06 1998-12-30 Japan Tobacco Inc. Composes chimiques et utilisation pharmaceutique
WO1998037061A1 (fr) * 1997-02-21 1998-08-27 Bayer Aktiengesellschaft Arylsulfonamides et leurs analogues, et procedes d'utilisation desdites substances pour traiter les maladies neurodegeneratives
WO1999002499A1 (fr) * 1997-07-11 1999-01-21 Japan Tobacco Inc. Composes quinoline et utilisations de ceux-ci en medecine
WO2000010968A2 (fr) * 1998-08-19 2000-03-02 Bayer Aktiengesellschaft Nouveaux esters d'aminoacides d'arylsulfonamides et leurs analogues
WO2000010967A1 (fr) * 1998-08-19 2000-03-02 Bayer Aktiengesellschaft Nouveaux arylsulfonamides et leurs analogues
WO2000016756A2 (fr) * 1998-09-24 2000-03-30 Innovet Italia S.R.L. Derives de n-acylvanillinamide capables d'activer des recepteurs peripheriques de cannabinoides
EP1142877A1 (fr) * 1999-01-08 2001-10-10 Japan Tobacco Inc. Composes de 2-oxoquinoline et leurs utilisations medicinales
WO2001004083A1 (fr) * 1999-07-07 2001-01-18 Innovet Italia S.R.L. Derives covalents d'alkanolamides d'acide monocarboxylique et dicarboxylique agissant de maniere fonctionnelle sur le recepteur cannabinoide cb2
WO2001028497A2 (fr) * 1999-10-18 2001-04-26 University Of Connecticut Nouveaux agonistes de cannabinoides bicycliques destines au recepteur de cannabinoides
WO2001028329A1 (fr) * 1999-10-18 2001-04-26 University Of Connecticut Ligands selectifs de recepteurs (cb2) de cannabinoides peripheriques
WO2001028557A1 (fr) * 1999-10-18 2001-04-26 University Of Connecticut Derives indoliques cannabimimetiques
WO2001032169A1 (fr) * 1999-10-31 2001-05-10 Yissum Research Development Company Of The Hebrew University Agonistes specifiques pour le recepteur peripherique de cannabinoides
WO2002010135A1 (fr) * 2000-08-01 2002-02-07 Ono Pharmaceutical Co., Ltd. Composes derives de 3,4-dihydroisoquinoline et medicaments contenant ces composes comme principe actif
WO2002026702A1 (fr) * 2000-09-26 2002-04-04 Bayer Aktiengesellschaft Sulfonates d'alcane de phenoxyphenyle
WO2002062750A1 (fr) * 2001-02-08 2002-08-15 Schering Corporation Ligands des recepteurs cannabinoides

Also Published As

Publication number Publication date
US20030232855A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
EP1807083B1 (fr) Utilisation de pirlindole pour traiter des maladies caracterisees par une proliferation de lymphocytes t et/ou une hyperproliferation de keratinocytes, en particulier une dermatite atopique et un psoriasis
AU2015326543B2 (en) 4-(4-(4-phenylureido-naphthalen-1-yl)oxy-pyridin-2-yl)amino-benzoic acid derivative as p38 kinase inhibitor
JP2002516274A (ja) ＩｇＥ影響特性を有する化合物
KR20150002642A (ko) 근위축성 측삭 경화증 치료용 신규 조성물
WO2003061699A1 (fr) Remedes pour affections allergiques
JPH11504044A (ja) 治療方法及び医薬製剤
WO2018039593A1 (fr) Traitement par ascaroside de l'oesophagite à éosinophiles
WO2004104000A1 (fr) Compose cyclique condense tricyclique et son utilisation medicale
US20040171613A1 (en) Therapeutic agent for non-immediate type allergic diseases
EP2991733A1 (fr) Cannabidiol destiné à la prévention et au traitement de la maladie du greffon contre l'hôte
WO2020106191A1 (fr) Production de glutarimide pour vaincre la résistance aux stéroïdes
US11439631B2 (en) Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
EP3761982A1 (fr) Traitement de maladies démyélinisantes
JPWO2006041121A1 (ja) 慢性皮膚疾患の治療および／または予防剤
WO2020135872A1 (fr) Composition pharmaceutique immunosuppressive et son application
JP2003252796A (ja) アレルギー疾患治療剤
EP3131545A2 (fr) Utilisation d'énoximone pour le traitement d'affections topiques associées au système immunitaire, dans une composition pharmaceutique ainsi que dans une préparation pharmaceutique
JP2005015422A (ja) 非即時型アレルギー疾患治療剤
EP1598079A1 (fr) Traitement de la dermatite de contact allergique
TW201842934A (zh) 抗過敏劑
WO2023202439A1 (fr) Utilisation der dérivé de composé diterpène ou de sel de celui-ci dans la préparation de médicament pour prévention et traitement d'une dermatite atopique
WO2004041280A1 (fr) Composition destinee a prevenir la secretion du facteur de liberation de l'histamine dependant de l'immunoglobuline e
WO2022162992A1 (fr) Composition pharmaceutique pour le traitement de l'allergie
WO2006062097A1 (fr) Agent pour la prévention et/ou le traitement du prurit
JPH08188533A (ja) タイプ２ヘルパーｔ細胞選択的免疫抑制剤

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 10375057

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase